Q2 EPS Estimate for Esperion Therapeutics Lifted by Analyst

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Analysts at Zacks Research boosted their Q2 2026 EPS estimates for Esperion Therapeutics in a note issued to investors on Wednesday, June 4th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will earn ($0.06) per share for the quarter, up from their prior estimate of ($0.07). The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics' Q3 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.20) EPS and FY2027 earnings at $0.09 EPS.

A number of other research firms also recently issued reports on ESPR. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Friday, April 25th. Needham & Company LLC decreased their price target on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. JMP Securities reissued a "market outperform" rating and issued a $4.00 price target (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. Finally, The Goldman Sachs Group decreased their price target on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $6.25.

Esperion Therapeutics Stock Down 1.6%

Shares of Esperion Therapeutics stock traded down $0.02 during trading on Friday, reaching $1.20. 3,756,761 shares of the stock were exchanged, compared to its average volume of 5,390,579. The stock's fifty day moving average is $0.96 and its 200 day moving average is $1.68. The firm has a market cap of $237.84 million, a price-to-earnings ratio of -1.88 and a beta of 0.67. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). The firm had revenue of $65.00 million for the quarter, compared to the consensus estimate of $54.97 million.

Hedge Funds Weigh In On Esperion Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Jones Financial Companies Lllp bought a new position in shares of Esperion Therapeutics during the first quarter valued at approximately $278,000. Graham Capital Management L.P. increased its stake in shares of Esperion Therapeutics by 153.5% during the first quarter. Graham Capital Management L.P. now owns 487,735 shares of the biopharmaceutical company's stock valued at $702,000 after purchasing an additional 295,320 shares in the last quarter. State of Wyoming increased its stake in shares of Esperion Therapeutics by 93.8% during the first quarter. State of Wyoming now owns 89,936 shares of the biopharmaceutical company's stock valued at $130,000 after purchasing an additional 43,526 shares in the last quarter. CW Advisors LLC bought a new position in shares of Esperion Therapeutics during the first quarter valued at approximately $74,000. Finally, Summit Financial LLC increased its stake in shares of Esperion Therapeutics by 40.1% during the first quarter. Summit Financial LLC now owns 65,194 shares of the biopharmaceutical company's stock valued at $94,000 after purchasing an additional 18,666 shares in the last quarter. Institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.